☆ 3.8 Article

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)

BMJ OPEN GASTROENTEROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study

Philip J. Smith et al.

Summary: The study aimed to evaluate the effectiveness of an elective switching program from IV infliximab to SC CT-P13 in IBD patients. Results showed high treatment persistence rates and low immunogenicity after the switch, with no significant change in disease activity or biomarkers. The study also found an increase in infliximab levels after switching, with only antibodies to infliximab associated with serum levels. Patient acceptance and satisfaction rates were high with SC CT-P13.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Article Medicine, General & Internal

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations

Gemma Burdge et al.

Summary: This study retrospectively investigated the uptake and rationale for switching from intravenous infusions to subcutaneous injections of infliximab (IFX) or vedolizumab (VDZ) for inflammatory bowel disease (IBD) treatment. The results showed that approximately 58% of IFX patients and VDZ patients chose to switch to subcutaneous treatment, and the decision to switch was not influenced by demographic or clinical factors. Questionnaire responses revealed that time savings were the primary motivator for patients to switch.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber et al.

Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative

Ajay M Verma et al.

Lancet Gastroenterology & Hepatology (2021)

Add to Collection

Article Medicine, General & Internal

Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: A brief UK stakeholder survey

Adrian Heald et al.

Summary: This study highlights the risk posed by COVID-19 to individuals with autoimmune conditions, such as rheumatoid arthritis and inflammatory bowel disease. It shows that switching from intravenous to subcutaneous biologics is driven by the pandemic, with subcutaneous administration being a more cost-effective option for many patients even without industry-funded home-care. The study also discusses the potential indirect benefits of subcutaneous administration, such as reduced risk of infection and patient costs.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)

Add to Collection

Article Medicine, General & Internal

Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease

Jose Maria Huguet et al.

Summary: This study analyzed clinical response rates and adverse events in IBD patients treated with CT-P13 in real-life practice. The results showed that CT-P13 is an effective and safe infliximab biosimilar for the treatment of IBD, with sustained clinical remission and response rates over 12 months.

WORLD JOURNAL OF CLINICAL CASES (2021)

Add to Collection

Review Immunology

An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases

Seung Wook Hong et al.

IMMUNOTHERAPY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Surgery in the age of biologics

Daniel J. Wong et al.

GASTROENTEROLOGY REPORT (2019)

Add to Collection

Review Medicine, General & Internal

The role of biologics in the treatment of patients with inflammatory bowel disease

Christian P. Selinger et al.

BRITISH JOURNAL OF HOSPITAL MEDICINE (2018)

Add to Collection

Article Gastroenterology & Hepatology

Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis

E. J. Mao et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)

Add to Collection

Review Gastroenterology & Hepatology

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients

Jorgen Jahnsen

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)

Add to Collection

Article Gastroenterology & Hepatology

A UK cost of care model for inflammatory bowel disease

Nivedita Ghosh et al.

FRONTLINE GASTROENTEROLOGY (2015)

Add to Collection

Article Gastroenterology & Hepatology

The Extra Burden of Infliximab Infusions in Inflammatory Bowel Disease

Anthony Buisson et al.

INFLAMMATORY BOWEL DISEASES (2013)

Add to Collection

Article Medicine, General & Internal

Infliximab for induction and maintenance therapy for ulcerative colitis

P Rutgeerts et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Medicine, General & Internal

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

SB Hanauer et al.

LANCET (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.